Reviewer’ s report
Title: Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis:A Case Report
Version: 0Date: 17 Apr 2020
Reviewer: Humberto Jijon
Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an
attachment. Please only upload as attachments annotated versions of manuscripts, graphs,supporting materials or other aspects of your report which cannot be included in a text format.Please overwrite this text when adding your comments to the authors.
The main to criticisms leading to my decision centre on 1) the grammar and language are poor and
significantly impair my ability to understand the article and detract from its general readability.These can be addressed by having a fluent English speaker or editing service work on the paper.2) The novelty of this paper at this point in time now is significantly reduced. Given theabundance of data on the topic, specially considering data from the anti-Il-17 clinical trials,Gastroenterologists are now aware of the contraindications associated with the use of anti-IL17blockers in the context of IBD. This patient had pre-existing IBD prior to the initiation of anti-IL-17 therapy, as such, perhaps publication in a Dermatology journal might be most appropriate.
One aspect that I find quite novel however is the description of dual response of psoriasis and
Crohn's disease to use of Il-23-specific blockade using guselkumab. I would refer the authors to
two papers, first a case report in IBD J 2019 by Grossberg, L and a review by Ma C et al., 2019.
This is a novel aspect that, if focus upon and expanded may help the authors get the present casepublished. Given the promise of anti-IL23 therapy in CD, this would anticipate their general usein IBD and potentially offer the use of IL-23-specific therapy for the dual treatment of CD andpsoriasis.
More specific comments: The abstract states that Crohn's disease is a skin disease, this is clearly a
cut and paste error. The background and abstract are almost identical, I would suggest rewordingto avoid redundancy.
line 36, do you mean SNPs or sites?Line 44, there is an early truncation of sentenceline 50, what is meant by patent?
line 55, did he or not have rectal bleeding
The timing and duration of treatments is very confusing.
The images I received a poor quality. If these are the best images, ideally they should be annotated
to highlight pathology.
Line 81, CT scan cannot assess stiffness
Line 69 and 70, sentence is repeated
Figure legends, panels a-c are presumably pre-anti-IL-17
The number of grammatical errors to address to large to consider point by point.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
YesDoes the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
YesAre the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?If an additional statistical review is recommended, please specify what aspects require furtherassessment in your comments to the editors.
I am able to assess the statisticsQuality of written English
Please indicate the quality of language in the manuscript:
Not suitable for publication unless extensively editedDeclaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
I declare I have no competing interestsI agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named reportincluding any attachments I upload will be posted on the website along with the authors'responses. I agree for my report to be made available under an Open Access Creative CommonsCC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any commentswhich I do not wish to be included in my named report can be included as confidential commentsto the editors, which will not be published.
I agree to the open peer review policy of the journal
Reviewer’ s report
Title: Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis:A Case Report
Version: 0Date: 17 Apr 2020
Reviewer: Humberto Jijon
Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an
attachment. Please only upload as attachments annotated versions of manuscripts, graphs,supporting materials or other aspects of your report which cannot be included in a text format.Please overwrite this text when adding your comments to the authors.
The main to criticisms leading to my decision centre on 1) the grammar and language are poor and
significantly impair my ability to understand the article and detract from its general readability.These can be addressed by having a fluent English speaker or editing service work on the paper.2) The novelty of this paper at this point in time now is significantly reduced. Given theabundance of data on the topic, specially considering data from the anti-Il-17 clinical trials,Gastroenterologists are now aware of the contraindications associated with the use of anti-IL17blockers in the context of IBD. This patient had pre-existing IBD prior to the initiation of anti-IL-17 therapy, as such, perhaps publication in a Dermatology journal might be most appropriate.
One aspect that I find quite novel however is the description of dual response of psoriasis and
Crohn's disease to use of Il-23-specific blockade using guselkumab. I would refer the authors to
two papers, first a case report in IBD J 2019 by Grossberg, L and a review by Ma C et al., 2019.
This is a novel aspect that, if focus upon and expanded may help the authors get the present casepublished. Given the promise of anti-IL23 therapy in CD, this would anticipate their general usein IBD and potentially offer the use of IL-23-specific therapy for the dual treatment of CD andpsoriasis.
More specific comments: The abstract states that Crohn's disease is a skin disease, this is clearly a
cut and paste error. The background and abstract are almost identical, I would suggest rewordingto avoid redundancy.
line 36, do you mean SNPs or sites?Line 44, there is an early truncation of sentenceline 50, what is meant by patent?
line 55, did he or not have rectal bleeding
The timing and duration of treatments is very confusing.
The images I received a poor quality. If these are the best images, ideally they should be annotated
to highlight pathology.
Line 81, CT scan cannot assess stiffness
Line 69 and 70, sentence is repeated
Figure legends, panels a-c are presumably pre-anti-IL-17
The number of grammatical errors to address to large to consider point by point.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
YesDoes the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
YesAre the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?If an additional statistical review is recommended, please specify what aspects require furtherassessment in your comments to the editors.
I am able to assess the statisticsQuality of written English
Please indicate the quality of language in the manuscript:
Not suitable for publication unless extensively editedDeclaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
I declare I have no competing interestsI agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named reportincluding any attachments I upload will be posted on the website along with the authors'responses. I agree for my report to be made available under an Open Access Creative CommonsCC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any commentswhich I do not wish to be included in my named report can be included as confidential commentsto the editors, which will not be published.
I agree to the open peer review policy of the journal
Please review this paper.
user
Reviewer’ s report
Title: Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis:A Case Report
Version: 0Date: 17 Apr 2020
Reviewer: Humberto Jijon
Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an
attachment. Please only upload as attachments annotated versions of manuscripts, graphs,supporting materials or other aspects of your report which cannot be included in a text format.Please overwrite this text when adding your comments to the authors.
The main to criticisms leading to my decision centre on 1) the grammar and language are poor and
significantly impair my ability to understand the article and detract from its general readability.These can be addressed by having a fluent English speaker or editing service work on the paper.2) The novelty of this paper at this point in time now is significantly reduced. Given theabundance of data on the topic, specially considering data from the anti-Il-17 clinical trials,Gastroenterologists are now aware of the contraindications associated with the use of anti-IL17blockers in the context of IBD. This patient had pre-existing IBD prior to the initiation of anti-IL-17 therapy, as such, perhaps publication in a Dermatology journal might be most appropriate.
One aspect that I find quite novel however is the description of dual response of psoriasis and
Crohn's disease to use of Il-23-specific blockade using guselkumab. I would refer the authors to
two papers, first a case report in IBD J 2019 by Grossberg, L and a review by Ma C et al., 2019.
This is a novel aspect that, if focus upon and expanded may help the authors get the present casepublished. Given the promise of anti-IL23 therapy in CD, this would anticipate their general usein IBD and potentially offer the use of IL-23-specific therapy for the dual treatment of CD andpsoriasis.
More specific comments: The abstract states that Crohn's disease is a skin disease, this is clearly a
cut and paste error. The background and abstract are almost identical, I would suggest rewordingto avoid redundancy.
line 36, do you mean SNPs or sites?Line 44, there is an early truncation of sentenceline 50, what is meant by patent?
line 55, did he or not have rectal bleeding
The timing and duration of treatments is very confusing.
The images I received a poor quality. If these are the best images, ideally they should be annotated
to highlight pathology.
Line 81, CT scan cannot assess stiffness
Line 69 and 70, sentence is repeated
Figure legends, panels a-c are presumably pre-anti-IL-17
The number of grammatical errors to address to large to consider point by point.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
YesDoes the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
YesAre the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?If an additional statistical review is recommended, please specify what aspects require furtherassessment in your comments to the editors.
I am able to assess the statisticsQuality of written English
Please indicate the quality of language in the manuscript:
Not suitable for publication unless extensively editedDeclaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
I declare I have no competing interestsI agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named reportincluding any attachments I upload will be posted on the website along with the authors'responses. I agree for my report to be made available under an Open Access Creative CommonsCC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any commentswhich I do not wish to be included in my named report can be included as confidential commentsto the editors, which will not be published.
I agree to the open peer review policy of the journal
assistant